Medpace Holdings, Inc. (NASDAQ:MEDP) Stake Lifted by Nisa Investment Advisors LLC

Posted by Defense World Staff on Apr 30th, 2023

Nisa Investment Advisors LLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) by 16.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,110 shares of the company’s stock after buying an additional 154 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Medpace were worth $236,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Raymond James & Associates grew its stake in Medpace by 11.9% during the 3rd quarter. Raymond James & Associates now owns 80,422 shares of the company’s stock worth $12,640,000 after buying an additional 8,562 shares during the last quarter. Gladstone Institutional Advisory LLC bought a new position in Medpace during the 4th quarter worth $302,000. Hancock Whitney Corp grew its stake in Medpace by 10.9% during the 3rd quarter. Hancock Whitney Corp now owns 45,820 shares of the company’s stock worth $7,202,000 after buying an additional 4,494 shares during the last quarter. AXA S.A. grew its stake in Medpace by 27.1% during the 3rd quarter. AXA S.A. now owns 44,600 shares of the company’s stock worth $7,010,000 after buying an additional 9,500 shares during the last quarter. Finally, Gabelli Funds LLC bought a new position in shares of Medpace in the third quarter worth $204,000. 82.49% of the stock is currently owned by institutional investors.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 31,648 shares of the firm’s stock in a transaction dated Tuesday, April 25th. The stock was sold at an average price of $221.83, for a total transaction of $7,020,475.84. Following the completion of the transaction, the chief executive officer now owns 6,451,371 shares of the company’s stock, valued at $1,431,107,628.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 25.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MEDP. Robert W. Baird increased their price target on Medpace from $226.00 to $233.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 15th. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research note on Wednesday.

Medpace Stock Up 1.3 %

Shares of MEDP stock opened at $200.14 on Friday. The stock has a 50-day simple moving average of $190.40 and a 200 day simple moving average of $204.30. Medpace Holdings, Inc. has a fifty-two week low of $128.99 and a fifty-two week high of $241.48. The stock has a market capitalization of $6.10 billion, a P/E ratio of 25.33 and a beta of 1.42.

Medpace (NASDAQ:MEDP – Get Rating) last announced its earnings results on Monday, April 24th. The company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $1.76 by $0.51. Medpace had a return on equity of 75.20% and a net margin of 16.44%. The business had revenue of $434.07 million during the quarter, compared to analysts’ expectations of $402.83 million. During the same quarter last year, the business posted $1.69 earnings per share. The company’s quarterly revenue was up 31.2% on a year-over-year basis. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 8.11 earnings per share for the current year.

Medpace Company Profile

(Get Rating)

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.